BACKGROUND AND AIMS: SARS-CoV-2 is a worldwide serious health problem and vaccination seems to have a crucial role in managing the COVID-19 pandemic. The aim of this prospective observational study was to monitor the trend of antibodies against SARS-CoV-2 after vaccination with BNT162b2 (COMIRNATY) in patients with inflammatory bowel disease treated by immunosuppressive and/or biological therapy, demonstrate whether any type of this therapy is associated with poorer production of antibodies against COVID-19 and evaluate the safety of vaccination against COVID-19 in these patients. METHODS: Eighty-seven eligible patients from one tertiary gastroenterological center with inflammatory bowel disease (60 with CD, 27 with UC) treated by immunosuppressive and/or biological therapy from the antiTNFα group were indicated to vaccination against SARS-CoV-2. Effectiveness of vaccination was evaluated by the values of antibodies before and 4 weeks after 2nd dose of vaccine. Additional goal was to evaluate adverse events of vaccination. RESULTS: Before the 2nd dose of vaccine, geometric mean of SARS-CoV-2 IgG antibodies were 40.7 U/ml in the biological therapy group, 34.8 U/ml in the azathioprine group and 44.8 U/ml in the combination therapy group of patients. The geometric means were 676.5.7 U/ml in the biological therapy group, 614.4 U/ml in the azathioprine group and 500.1 U/ml in the combination therapy group of patients four weeks after 2nd dose. Statistically significant differences between these groups were not proved. Several non-severe local and general adverse events were present in our patients with a majority of these events on the day of vaccine administration and the day after, no anaphylactic reactions were present. CONCLUSIONS: Our measurements proved the efficacy and safety of vaccination against SARS-CoV-2 in patients with inflammatory bowel disease treated by immunosuppressive and/or biological therapy. Statistically significant differences between our groups of patients were not proved.

1st Department of Infectious Diseases 2nd Medical Faculty Charles University Prague and Hospital Na Bulovce Prague Czech Republic

Department of Immunology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Internal Medicine 2nd Faculty of Medicine Charles University Prague and Motol University Hospital Prague Czech Republic

Department of Pediatric Surgery 2nd Faculty of Medicine Charles University Prague and University Hospital Motol Prague Czech Republic

Laboratory of Cellular and Molecular Immunology Institute of Microbiology of the Czech Academy of Sciences Prague Czech Republic

See more in PubMed

Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2021. Jan;174(1):69–79. doi: 10.7326/M20-5008 Epub 2020 Sep 17. ; PMCID: PMC7505025. PubMed DOI PMC

Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al.. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med. 2020. Feb 27;382(9):872–874. doi: 10.1056/NEJMc2001272 PubMed DOI PMC

Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020. Apr;10(2):102–108. doi: 10.1016/j.jpha.2020.03.001 Epub 2020 Mar 5. ; PMCID: PMC7104082. PubMed DOI PMC

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al.. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. May;8(5):475–481. doi: 10.1016/S2213-2600(20)30079-5 PubMed DOI PMC

Feldman M, Friedman L, Bramdt L, et al.. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management. 11th ed. Philadelphia (PA): Elsevier; 2021. p. 1868–1929.

Baumgart D. Crohn’s disease and ulcerative colitis from epidemiology and immunobiology to a rational diagnostic and therapeutic approach. 1st ed. New York (NY): Springer; 2012. p. 3–74.

Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al.. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119–24. doi: 10.1038/nature11582 PubMed DOI PMC

Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al.. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014. Jun;8(6):443–68. doi: 10.1016/j.crohns.2013.12.013 PubMed DOI

Macaluso FS, Orlando A. COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. Dig Liver Dis. 2020. Nov;52(11):1222–1227. doi: 10.1016/j.dld.2020.09.002 PubMed DOI PMC

Maconi G, Bosetti C, De Monti A, Boyapati RK, Shelton E, Piazza N, et al.. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. Dig Liver Dis. 2021. Mar;53(3):263–270. doi: 10.1016/j.dld.2020.12.013 PubMed DOI PMC

Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al.. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020. Aug;159(2):481–491.e3 doi: 10.1053/j.gastro.2020.05.032 PubMed DOI PMC

Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020. Oct;586(7830):516–527. doi: 10.1038/s41586-020-2798-3 PubMed DOI

Habas K, Nganwuchu C, Shahzad F, Gopalan R, Haque M, Rahman S, et al.. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther. 2020 Dec;18(12):1201–1211. doi: 10.1080/14787210.2020.1797487 PubMed DOI

Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al.. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020. Jun;20(6):669–677. doi: 10.1016/S1473-3099(20)30243-7 PubMed DOI PMC

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020. May 26;323(20):2052–2059. doi: 10.1001/jama.2020.6775 PubMed DOI PMC

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al.. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020. Aug;584(7821):430–436. doi: 10.1038/s41586-020-2521-4 PubMed DOI PMC

Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al.. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020. May 22;369:m1966. doi: 10.1136/bmj.m1966 PubMed DOI PMC

Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020. Sep 10;17(9):e1003321. doi: 10.1371/journal.pmed.1003321 PubMed DOI PMC

Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020. Jul;159(1):350–357. doi: 10.1053/j.gastro.2020.04.012 PubMed DOI PMC

Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al.. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021. Apr;70(4):725–732. doi: 10.1136/gutjnl-2020-322539 PubMed DOI PMC

Marion O, Del Bello A, Abravanel F, Couat C, Faguer S, Esposito L, et al.. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Ann Intern Med. 2021. Sep;174(9):1336–1338. doi: 10.7326/M21-1341 PubMed DOI PMC

Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al.. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021. Jun 1;325(21):2204–2206. doi: 10.1001/jama.2021.7489 PubMed DOI PMC

Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, et al.. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021. Mar;6(3):218–224. doi: 10.1016/S2468-1253(21)00024-8 PubMed DOI PMC

Siegel CA, Melmed GY, McGovern DP, Rai V, Krammer F, Rubin DT, et al.. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021. Apr;70(4):635–640. doi: 10.1136/gutjnl-2020-324000 PubMed DOI PMC

Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, et al.. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep. 2021. Jul;3(4):212–228. doi: 10.1002/ygh2.473 PubMed DOI PMC

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020. Dec 31;383(27):2603–2615. doi: 10.1056/NEJMoa2034577 PubMed DOI PMC

Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al.. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021. May 15;397(10287):1819–1829. doi: 10.1016/S0140-6736(21)00947-8 PubMed DOI PMC

Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al.. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021. May 8;397(10286):1725–1735. doi: 10.1016/S0140-6736(21)00790-X PubMed DOI PMC

Benenson S, Oster Y, Cohen MJ, Nir-Paz R. BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers. N Engl J Med. 2021. May 6;384(18):1775–1777. doi: 10.1056/NEJMc2101951 PubMed DOI PMC

Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, et al.. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021. Oct;70(10):1884–1893. doi: 10.1136/gutjnl-2021-324789 PubMed DOI

Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al.. First Month of COVID-19 Vaccine Safety Monitoring—United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021. Feb 26;70(8):283–288. doi: 10.15585/mmwr.mm7008e3 PubMed DOI PMC